ArticleAntimicrobial agents and chemotherapy2020
Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.
Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 49 citations in OpenAlex.
- Review
- Current and emerging therapies for fungal biofilms and systemic infections.Critical reviews in microbiology · 2026Review
- Inhibition mechanism of the fungal β-1,3-glucan synthases by triterpenoid antifungal drugs.Nature communications · 2026Article
- Pathologic evaluation of Syzygium aromaticum essential oil against pulmonary aspergillosis in non-neutropenic immunosuppressed rabbits.Scientific reports · 2026Article
- Azole-ResistantJournal of fungi (Basel, Switzerland) · 2025Review
- Invasive Aspergillosis in the Intensive Care Unit.Journal of fungi (Basel, Switzerland) · 2025Review
- New antifungal strategies and drug development against WHO critical priority fungal pathogens.Frontiers in cellular and infection microbiology · 2025Review
- Immune markers for pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a narrative review.Frontiers in immunology · 2025Review
- The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives.Current research in microbial sciences · 2025Review
- Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.Clinical microbiology reviews · 2024Review
- Brilacidin, a host defense peptide mimetic, potentiates ibrexafungerp antifungal activity against the human pathogenic fungusbioRxiv : the preprint server for biology · 2024Article
- Ibrexafungerp: A narrative overview.Current research in microbial sciences · 2024Review
- Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections.Journal of fungi (Basel, Switzerland) · 2022Review
- Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents.Journal of fungi (Basel, Switzerland) · 2022Review
- The Feasibility of Ibrexafungerp for the Treatment of Fungal Infections in Patients with Hematological Malignancies.Journal of fungi (Basel, Switzerland) · 2022Article
- Pharmacokinetics and Pharmacodynamics of Ibrexafungerp.Drugs in R&D · 2022Review
- Advances in anti-fungal therapies.Mycopathologia · 2021Review
- The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.Drugs · 2021Review
- Ibrexafungerp: First Approval.Drugs · 2021Review
- In Vitro Activity of Ibrexafungerp against a Collection of Clinical Isolates ofJournal of fungi (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ibrexafungerp (formerly SCY-078) is a semisynthetic triterpenoid and potent (1→3)-β-d-glucan synthase inhibitor. We investigated the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.